Defence Therapeutics Inc.
DTCFF
$0.60
-$0.03-5.11%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.23% | -15.36% | -29.24% | 54.85% | -0.05% |
| Total Depreciation and Amortization | 13.01% | -3.15% | -2.31% | -63.38% | 112.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.89% | 28.63% | 44.84% | 20.02% | 54.69% |
| Change in Net Operating Assets | 105.36% | -840.96% | -128.60% | -19.16% | 126.23% |
| Cash from Operations | 57.21% | -191.25% | -844.93% | 116.48% | 44.28% |
| Capital Expenditure | -- | -- | -- | -- | 107.82% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -100.00% | -- | -- | 107.82% |
| Total Debt Issued | -- | -- | -100.00% | -70.00% | -- |
| Total Debt Repaid | 85.33% | 82.63% | -365.83% | -256.41% | 0.00% |
| Issuance of Common Stock | -100.00% | 426.88% | -- | -- | -98.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.21% | -1,056.07% | -- | -- | 100.00% |
| Cash from Financing | -100.27% | 492.80% | 5,032.98% | -122.49% | -95.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -145.09% | 271,720.00% | -100.91% | 116.34% | -375.93% |